Prospective Study Of Icotinib Concurrent IMRT In Patients With StageⅢb Non-small Cell Lung Cancer

Objective:To evaluate the safety profile and efficacy of icotinib concurrent with intensity modulated conformal radiotherapy (IMRT) in previously untreated patients with Stage Ⅲb non-small cell lung cancer (NSCLC).Method:From November2010until September2013,90patients were entered onto the trial, and78patients for eligibility assessment.24patients were treated with icotinib concurrent IMRT.27patients were treated with icotinib monotherapy and27patients to the TP concurrent chemoradiotherapy group. Patients received docetaxel20mg/m2intravenously (IV) on days1, and cisplatin30mg/m2IV on days1,1time/week,8times. Icotinib was given orally in as dose of125mg8-hourly. IMRT was administered as2.0Gy daily treatments5days a week for a total of30fractions. The total dose of IMRT was60Gy in30fractions. A two-tailed P<0.05was considered significant.Result:The primary endpoints were overall survival (OS). The secondary endpoints included progression free survival (PFS), local control rate and acute toxicity. Loss of appetite, leucopenia, rash were acceptable and manageable. Severe adverse events included pain (Grade4,12.5%) and leucopenia (Grade4,4.17%), rash (Grade4,4.17%). With a median follow-up of566days, a local control rate of95.8%was achieved for thoracic tumor. Overall survival and median PFS were671.622days,363days.Conclusion:The current experimental data suggested that icotinib concomitant IMRT was effective and safe for patients with Ⅲb NSCLC as first-line regimen.